MediciNova (MNOV) Competitors $1.27 0.00 (-0.31%) As of 07/11/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV vs. CRDF, FENC, VOR, INBX, CGC, LIMN, ESPR, BTMD, NBTX, and PRQRShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Cardiff Oncology (CRDF), Adherex Technologies (FENC), Vor Biopharma (VOR), Inhibrx Biosciences (INBX), Canopy Growth (CGC), Liminatus Pharma (LIMN), Esperion Therapeutics (ESPR), biote (BTMD), Nanobiotix (NBTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. MediciNova vs. Its Competitors Cardiff Oncology Adherex Technologies Vor Biopharma Inhibrx Biosciences Canopy Growth Liminatus Pharma Esperion Therapeutics biote Nanobiotix ProQR Therapeutics MediciNova (NASDAQ:MNOV) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Do institutionals and insiders believe in MNOV or CRDF? 9.9% of MediciNova shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 13.6% of MediciNova shares are held by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, MNOV or CRDF? MediciNova has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Which has preferable earnings and valuation, MNOV or CRDF? MediciNova has higher revenue and earnings than Cardiff Oncology. MediciNova is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediciNova$1M62.29-$11.04M-$0.23-5.52Cardiff Oncology$680K398.20-$45.43M-$0.92-4.42 Is MNOV or CRDF more profitable? MediciNova has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. MediciNova's return on equity of -20.77% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets MediciNovaN/A -20.77% -19.68% Cardiff Oncology -8,308.50%-76.45%-62.85% Does the media refer more to MNOV or CRDF? In the previous week, Cardiff Oncology had 4 more articles in the media than MediciNova. MarketBeat recorded 6 mentions for Cardiff Oncology and 2 mentions for MediciNova. MediciNova's average media sentiment score of 0.94 beat Cardiff Oncology's score of 0.65 indicating that MediciNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MNOV or CRDF? MediciNova presently has a consensus target price of $7.00, suggesting a potential upside of 451.18%. Cardiff Oncology has a consensus target price of $11.70, suggesting a potential upside of 187.47%. Given MediciNova's stronger consensus rating and higher probable upside, research analysts clearly believe MediciNova is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryMediciNova beats Cardiff Oncology on 11 of the 17 factors compared between the two stocks. Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.29M$2.93B$5.54B$9.08BDividend YieldN/A2.45%5.06%4.02%P/E Ratio-5.5220.9928.2820.33Price / Sales62.29286.30422.39100.72Price / CashN/A41.0526.2427.98Price / Book1.197.638.125.50Net Income-$11.04M-$55.05M$3.19B$250.38M7 Day Performance1.60%7.11%3.69%2.19%1 Month Performance-4.51%8.14%7.70%10.92%1 Year Performance-11.73%1.62%29.35%16.41% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova1.637 of 5 stars$1.27flat$7.00+451.2%-11.7%$62.29M$1M-5.5210CRDFCardiff Oncology1.2666 of 5 stars$3.65-0.3%$9.88+170.5%+62.2%$243.49M$680K-3.9720FENCAdherex Technologies2.2036 of 5 stars$8.47-3.8%$13.00+53.5%+37.4%$242.88M$47.54M-16.6110News CoverageAnalyst UpgradeVORVor Biopharma0.7463 of 5 stars$2.67+39.8%N/AN/A$238.67MN/A0.00140Gap UpINBXInhibrx Biosciences2.2471 of 5 stars$18.35+12.4%N/A+63.8%$236.39M$200K0.16166High Trading VolumeCGCCanopy Growth0.409 of 5 stars$1.20-6.3%$2.00+66.7%-82.6%$235.35M$225.65M-0.303,150LIMNLiminatus PharmaN/A$6.93-23.2%N/AN/A$234.65MN/A0.00N/ANews CoverageAnalyst UpgradeGap DownESPREsperion Therapeutics3.9738 of 5 stars$1.11-5.1%$7.00+530.6%-52.6%$231.89M$332.31M-1.39200News CoverageAnalyst RevisionBTMDbiote3.2612 of 5 stars$3.99-5.5%$8.00+100.5%-49.6%$230.88M$199.38M6.54194NBTXNanobiotix2.7998 of 5 stars$4.75-2.5%$8.00+68.6%-7.2%$229.54M$39.18M0.00100PRQRProQR Therapeutics2.5407 of 5 stars$2.14-1.8%$8.00+273.8%+25.4%$229.36M$20.46M-6.11180Analyst Forecast Related Companies and Tools Related Companies CRDF Competitors FENC Competitors VOR Competitors INBX Competitors CGC Competitors LIMN Competitors ESPR Competitors BTMD Competitors NBTX Competitors PRQR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNOV) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNOV Stock Alerts